Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Russia, Africa, and Asia.
Excellent balance sheet with reasonable growth potential.
Share Price & News
How has Genus's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GBE has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GBE exceeded the German Biotechs industry which returned 6.2% over the past year.
Return vs Market: GBE exceeded the German Market which returned 15% over the past year.
Price Volatility Vs. Market
How volatile is Genus's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Genus undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: GBE (€38.44) is trading above our estimate of fair value (€21.99)
Significantly Below Fair Value: GBE is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GBE is poor value based on its PE Ratio (258.2x) compared to the Biotechs industry average (43.8x).
PE vs Market: GBE is poor value based on its PE Ratio (258.2x) compared to the German market (21.1x).
Price to Earnings Growth Ratio
PEG Ratio: GBE is poor value based on its PEG Ratio (9.2x)
Price to Book Ratio
PB vs Industry: GBE is overvalued based on its PB Ratio (4.1x) compared to the DE Biotechs industry average (3.5x).
How is Genus forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GBE's forecast earnings growth (28.2% per year) is above the savings rate (-0.4%).
Earnings vs Market: GBE's earnings (28.2% per year) are forecast to grow faster than the German market (13.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: GBE's revenue (7.1% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: GBE's revenue (7.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GBE's Return on Equity is forecast to be low in 3 years time (9.6%).
How has Genus performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GBE has a large one-off loss of £36.5M impacting its June 30 2019 financial results.
Growing Profit Margin: GBE's current net profit margins (1.6%) are lower than last year (9.1%).
Past Earnings Growth Analysis
Earnings Trend: GBE's earnings have declined by -9.8% per year over the past 5 years.
Accelerating Growth: GBE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GBE had negative earnings growth (-81.7%) over the past year, making it difficult to compare to the Biotechs industry average (-4.7%).
Return on Equity
High ROE: GBE's Return on Equity (1.3%) is considered low.
Return on Assets
Return on Capital Employed
How is Genus's financial position?
Financial Position Analysis
Short Term Liabilities: GBE's short term assets (£209.2M) exceed its short term liabilities (£104.2M).
Long Term Liabilities: GBE's short term assets (£209.2M) do not cover its long term liabilities (£217.6M).
Debt to Equity History and Analysis
Debt Level: GBE's debt to equity ratio (20.7%) is considered satisfactory.
Reducing Debt: GBE's debt to equity ratio has reduced from 29.6% to 20.7% over the past 5 years.
Debt Coverage: GBE's debt is well covered by operating cash flow (32.1%).
Interest Coverage: GBE's interest payments on its debt are well covered by EBIT (14.8x coverage).
Inventory Level: GBE has a low level of unsold assets or inventory.
Debt Coverage by Assets: GBE's debt is covered by short term assets (assets are 2x debt).
What is Genus's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: GBE's dividend (0.87%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.31%).
High Dividend: GBE's dividend (0.87%) is low compared to the top 25% of dividend payers in the German market (3.59%).
Stability and Growth of Payments
Stable Dividend: GBE's dividend payments have been volatile in the past 10 years.
Growing Dividend: GBE's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (224.2%), GBE's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: GBE's dividends in 3 years are forecast to be well covered by earnings (36% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stephen Wilson (59yo)
Mr. Stephen Wilson serves as Chief Executive Officer and Director of Genus plc since September 13, 2019. Mr. Wilson served as Group Finance Director of Genus plc since March 1, 2013 and served as its Execu ...
CEO Compensation Analysis
Compensation vs Market: Stephen's total compensation ($USD1.96M) is about average for companies of similar size in the German market ($USD2.02M).
Compensation vs Earnings: Stephen's compensation has been consistent with company performance over the past year.
|CEO & Director||0.4yrs||UK£1.51m||0.16% £4.0m|
|CFO & Director||0.08yrs||no data||no data|
|Chief Operating Officer||0yrs||no data||0.10% £2.6m|
|Head of R&D and Chief Scientific Officer||0.6yrs||no data||no data|
|Group General Counsel & Company Secretary||5.7yrs||no data||0.093% £2.3m|
|Group Human Resources Director||2.6yrs||no data||no data|
|Chief Operating Officer of Genus ABS Beef||7.6yrs||no data||no data|
|Chief Operating Officer of Genus ABS Dairy||3yrs||no data||no data|
|Group Financial Controller||0yrs||no data||no data|
Experienced Management: GBE's management team is considered experienced (2.6 years average tenure).
|CEO & Director||0.4yrs||UK£1.51m||0.16% £4.0m|
|CFO & Director||0.08yrs||no data||no data|
|Independent Non-Executive Director||1.6yrs||UK£55.00k||no data|
|Senior Independent Non-Executive Director||1.3yrs||UK£57.00k||0.0031% £76.6k|
|Independent Non-Executive Chairman||9.3yrs||UK£171.00k||0.013% £327.9k|
|Non-Executive Director||5.6yrs||UK£60.00k||0.0058% £143.8k|
|Independent Non-Executive Director||3.8yrs||UK£61.00k||no data|
Experienced Board: GBE's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.1%.
Genus plc's company bio, employee growth, exchange listings and data sources
- Name: Genus plc
- Ticker: GBE
- Exchange: DB
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£2.063b
- Listing Market Cap: UK£2.479b
- Shares outstanding: 64.67m
- Website: https://www.genusplc.com
Number of Employees
- Genus plc
- Matrix House
- Basing View
- RG21 4DZ
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GNS||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||GBP||Jan 1998|
|GENS.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jan 1998|
|GBE||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jan 1998|
|GNSL||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||GBP||Jan 1998|
Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates in three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers. The company has a strategic porcine collaboration with Beijing Capital Agribusiness Co. Ltd to research, develop, register, and market porcine reproductive and respiratory syndrome virus resistant pigs. Genus plc was incorporated in 1994 and is based in Basingstoke, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/16 22:15|
|End of Day Share Price||2020/02/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.